Skip to main content
Equibles
CLSDQ logo

CLSDQ · Clearside Biomedical, Inc. · Metrics

Track CLSDQ — free

Use CLSDQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLSDQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”
View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Volume — Avg daily vol (3M) —

CLSDQ metrics

51 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
—
Market cap
$1.30M

Price action

23 metrics
Price change (1W)
—
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
5.23M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 255.4%
P / book
—
FCF yield
-1,668.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,994.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-27

Profitability

9 metrics
Gross margin
88.1%
Operating margin
-689.8%
Trailing 12 months
Net margin
-780.9%
Gross profit (TTM)
$2.93M
Operating profit (TTM)
−$22.96M
Net income (TTM)
−$26.00M
Trailing 12 months
Diluted EPS (TTM)
$-2.35
FCF margin
-653.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.65
Gross profit per diluted share (TTM)
$0.57
Operating profit per diluted share (TTM)
$-4.46
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-5.06
Operating cash flow per diluted share (TTM)
$-4.13
Free cash flow per diluted share (TTM)
$-4.22
Capital expenditures per diluted share (TTM)
$0.09
R&D per diluted share (TTM)
$2.58
Stock compensation per diluted share (TTM)
$0.65
Book value per share
$-7.61

Growth

11 metrics
Revenue growth YoY
-80.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.0%
Year over year · more shares
Revenue CAGR (3Y)
-61.7%
Revenue CAGR (5Y)
-5.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-223.3%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$23.02M
Free cash flow (TTM)
−$21.75M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.80M
Total assets
$11.64M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$21.29M
Capital expenditures (TTM)
$453,000
R&D (TTM)
$13.22M
SG&A (TTM)
—
Stock compensation (TTM)
$3.33M
R&D / revenue
397.2%
Stock compensation / revenue
99.9%

Ownership (13F)

9 metrics
13F filers
1
13F filer change QoQ
0
Institutional ownership
0.5%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.0%
Holder tenure
3.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1539029 CUSIP 185063203 Visit website Investor relations